-
公开(公告)号：US20050070529A1
公开(公告)日：2005-03-31
申请号：US10467793
申请日：2002-01-15
申请人： Arne Sutter , Thomas Ehring , Thomas Welge , Klause Minck , Claudia Wilm , Michael Gassen , Hans-Michael Eggenweiler , Michael Wolf , Pierre Schelling , Norbert Beier , Joachim Leibrock
发明人： Arne Sutter , Thomas Ehring , Thomas Welge , Klause Minck , Claudia Wilm , Michael Gassen , Hans-Michael Eggenweiler , Michael Wolf , Pierre Schelling , Norbert Beier , Joachim Leibrock
IPC分类号： A61K31/50 , A61K31/501 , A61K31/535 , A61K31/5395 , A61K31/54 , A61K31/549 , A61P9/00 , A61P29/00 , A61P37/02
CPC分类号： A61K31/50 , A61K31/5395 , A61K31/549
摘要： The invention relates to the use of type 4 phosphodiesterase inhibitors to treat myocardial diseases.
摘要翻译： 本发明涉及使用4型磷酸二酯酶抑制剂来治疗心肌疾病。
-
2.发明授权4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1,2,4)triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies 失效具有PDE-IV抑制和TNF拮抗作用的4-（亚苄基 - 氨基）-3-（甲基硫烷基）-4h-（1,2,4）三嗪-5-酮衍生物，用于治疗心脏病和过敏公开(公告)号：US07485639B2
公开(公告)日：2009-02-03
申请号：US10484172
申请日：2002-06-19
申请人： Hans-Michael Eggenweiler , Michael Wolf , Norbert Beier , Joachim Leibrock , Pierre Schelling , Michael Gassen , Thomas Ehring
发明人： Hans-Michael Eggenweiler , Michael Wolf , Norbert Beier , Joachim Leibrock , Pierre Schelling , Michael Gassen , Thomas Ehring
IPC分类号： A01N43/64 , A61K31/53 , C07D253/00
CPC分类号： C07D253/075 , C07D401/12
摘要： Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R1, R2, A and R5 are as defined in Claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and AIDS, furthermore for inhibiting the formation of TNFα.
摘要翻译： 式（I）的三嗪衍生物及其生理上可接受的盐和溶剂化物，其中R1，R2，A和R5如权利要求1所定义，表现出磷酸二酯酶IV抑制作用，可用于治疗过敏性疾病，哮喘，慢性 支气管炎，特应性皮炎，牛皮癣和其他皮肤疾病，炎性疾病，自身免疫疾病，例如类风湿性关节炎，多发性硬化，克罗恩病，糖尿病或溃疡性结肠炎，骨质疏松症，移植排斥反应，恶病质，肿瘤生长或肿瘤 转移，败血症，记忆障碍，动脉粥样硬化和AIDS，此外用于抑制TNFα的形成。
-
公开(公告)号：US07312328B2
公开(公告)日：2007-12-25
申请号：US10451393
申请日：2001-12-19
申请人： Hans-Michael Eggenweiler , Michael Wolf , Norbert Beier , Joachim Leibrock , Michael Gassen , Thomas Ehring
发明人： Hans-Michael Eggenweiler , Michael Wolf , Norbert Beier , Joachim Leibrock , Michael Gassen , Thomas Ehring
IPC分类号： A61K31/50 , A61K31/495
CPC分类号： C07D403/12 , C07D237/04
摘要： This invention relates to compounds of the formula (I) in which R1, R2, R3, X and Q are as defined above and their use as PDE IV inhibitors.
摘要翻译： 本发明涉及其中R 1，R 2，R 3，X和Q如上定义的式（I）化合物 并将其用作PDE IV抑制剂。
-
公开(公告)号：US20060270676A1
公开(公告)日：2006-11-30
申请号：US11497235
申请日：2006-08-02
IPC分类号： A61K31/501 , A61K31/50 , C07D403/02
CPC分类号： C07D403/12 , C07D237/04
摘要： Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′ and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
摘要翻译： 式（I）的肼 - 丙腈衍生物其中R 1，R 2，R 3，R 3， SUP>和R 4具有权利要求1中给出的含义作为磷酸二酯酶IV抑制剂，并且可用于治疗骨质疏松症，肿瘤，恶病质，动脉粥样硬化，类风湿性关节炎，多发性硬化，糖尿病，炎性 过程，过敏，哮喘，自身免疫性疾病，心肌疾病和艾滋病。
-
公开(公告)号：US07544684B2
公开(公告)日：2009-06-09
申请号：US11497235
申请日：2006-08-02
IPC分类号： A61K31/50 , A61K31/501 , A61P11/06
CPC分类号： C07D403/12 , C07D237/04
摘要： Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′ and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
摘要翻译： 其中R 1，R 2，R 3，R 3'和R 4具有权利要求1中给出的含义的式（I）的肼基 - 丙腈衍生物作为磷酸二酯酶IV抑制剂起作用，可用于治疗骨质疏松症，恶病质，恶病质，动脉粥样硬化， 类风湿关节炎，多发性硬化，糖尿病，炎症过程，过敏，哮喘，自身免疫性疾病，心肌疾病和艾滋病。
-
公开(公告)号：US07141572B2
公开(公告)日：2006-11-28
申请号：US10494631
申请日：2002-10-10
IPC分类号： C07D403/12 , C07D237/04 , A61K31/501 , A61K31/50 , A61P11/06
CPC分类号： C07D403/12 , C07D237/04
摘要： Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′ and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS
摘要翻译： 式（I）的肼 - 丙腈衍生物其中R 1，R 2，R 3，R 3， SUP>和R 4具有权利要求1中给出的含义作为磷酸二酯酶IV抑制剂，并且可用于治疗骨质疏松症，肿瘤，恶病质，动脉粥样硬化，类风湿性关节炎，多发性硬化，糖尿病，炎性 过程，过敏，哮喘，自身免疫性疾病，心肌疾病和艾滋病
-
公开(公告)号：US20070293579A1
公开(公告)日：2007-12-20
申请号：US11676990
申请日：2007-02-20
申请人： Franz-Werner Kluxen , Bernd Hentsch , Claudia Wilm , Marian Braendle , Thomas Ehring , Thomas Eschenghagen , Oliver Zolk
发明人： Franz-Werner Kluxen , Bernd Hentsch , Claudia Wilm , Marian Braendle , Thomas Ehring , Thomas Eschenghagen , Oliver Zolk
IPC分类号： A61K31/145 , A61P9/00 , C12Q1/68 , G01N33/50
CPC分类号： A61K49/0008 , A61K31/145 , G01N2500/10
摘要： The present invention relates to the novel finding that inhibition of human CARP protein or of CARP DNA/mRNA may successfully cure heart disorders, especially heart failure in humans. The invention relates, therefore, to pharmaceutical compositions containing substances, preferably of lower molecular weight, which may influence the activity of cardiac CARP. The invention relates, furthermore, to a method of treatment heart failure using CARP inhibitory compounds, to methods for screening these inhibitors and to the use of CARP as diagnostic tool.
摘要翻译： 本发明涉及抑制人类CARP蛋白或CARP DNA / mRNA的新发现，可以成功地治愈心脏病，特别是人类的心力衰竭。 因此，本发明涉及含有可能影响心脏CARP活性的物质，优选较低分子量的药物组合物。 本发明还涉及使用CARP抑制化合物治疗心力衰竭的方法，用于筛选这些抑制剂的方法以及使用CARP作为诊断工具。
-
8.发明申请Inhibition of tristetraproline for protection of the heart from cardiac injuries 审中-公开抑制四仲素以保护心脏免受心脏损伤公开(公告)号：US20050084860A1
公开(公告)日：2005-04-21
申请号：US10498238
申请日：2002-11-30
申请人： Franz-Werner Kluxen , Bernd Hentsch , Thomas Ehring , Marian Brandle , Jorg Hoheisel , Marcus Frohme , Dimitri Zubakov
发明人： Franz-Werner Kluxen , Bernd Hentsch , Thomas Ehring , Marian Brandle , Jorg Hoheisel , Marcus Frohme , Dimitri Zubakov
IPC分类号： G01N33/53 , A61K31/7088 , A61K39/395 , A61K48/00 , A61P9/04 , A61P9/10 , A61P43/00 , C07K16/18 , C12N15/09 , C12Q1/68 , G01N33/566 , G01N33/68
CPC分类号： G01N33/6863 , G01N2333/525
摘要： The present invention relates to compounds suitable for the treatment of conditions which may be improved, at least in part, by increasing TNF α production. The invention further relates to assays for the identification of an individual at increased risk for or suffering from such conditions and to methods of screening compounds for their ability to enhance TNF α biosysthesis.
摘要翻译： 本发明涉及适用于治疗可通过增加TNFα产生而至少部分改善的病症的化合物。 本发明进一步涉及用于鉴定患有这种病症的风险增加或患有这种病症的个体的测定方法以及筛选化合物增强TNFα生物学修饰能力的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.05 秒)
